Comparative Pharmacology
Head-to-head clinical analysis: DELFLEX W DEXTROSE 4 25 LOW MAGNESIUM IN PLASTIC CONTAINER versus DELFLEX LM W DEXTROSE 2 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DELFLEX W DEXTROSE 4 25 LOW MAGNESIUM IN PLASTIC CONTAINER versus DELFLEX LM W DEXTROSE 2 5 IN PLASTIC CONTAINER.
DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM IN PLASTIC CONTAINER vs DELFLEX-LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Delflex with Dextrose 4.25% Low Magnesium is a peritoneal dialysis solution that uses dextrose as an osmotic agent to create a concentration gradient across the peritoneal membrane, allowing for the removal of uremic toxins and excess fluid via ultrafiltration. The low magnesium concentration (0.25 mEq/L) helps prevent hypermagnesemia in patients with renal failure.
Delflex-LM with Dextrose 2.5% is a peritoneal dialysis solution. Dextrose provides osmotic gradient for ultrafiltration; lactate (LM) is a bicarbonate precursor that buffers metabolic acidosis. The solution replaces fluid and electrolytes while removing waste products via diffusion and convection across the peritoneal membrane.
Continuous ambulatory peritoneal dialysis (CAPD)Continuous cycling peritoneal dialysis (CCPD)
Continuous ambulatory peritoneal dialysis (CAPD)Continuous cycling peritoneal dialysis (CCPD)
Intraperitoneal administration: 2 L per exchange, 4 exchanges daily. Dextrose concentration (1.5%, 2.5%, or 4.25%) determined by ultrafiltration needs. Low magnesium formulation selected based on serum magnesium levels.
Intraperitoneal administration: 2 liters of 2.5% dextrose solution per exchange, typically 4 exchanges daily (8 liters total). Adjust volume and frequency based on patient's dry weight, residual renal function, and peritoneal membrane transport characteristics.
None Documented
None Documented
Intraperitoneal dextrose: absorption half-life ~1.5-2 hours; elimination of absorbed glucose follows endogenous glucose kinetics (t1/2 ~1-2 hours). Clinical note: Continuous dwell results in steady-state concentrations.
Dextrose: ~1-2 hours for plasma glucose levels; lactate: ~30-60 minutes for conversion to bicarbonate.
Dextrose is metabolized via glycolysis and the citric acid cycle; magnesium is excreted renally and undergoes reabsorption in the kidneys; other electrolytes are regulated by renal function. No specific enzyme induction or inhibition noted.
Dextrose is metabolized via glycolysis and oxidative phosphorylation; lactate is converted to bicarbonate in the liver and kidneys via lactate dehydrogenase.
Primarily renal (peritoneal clearance): ~60-80% of glucose absorbed is metabolized; dextrose metabolites (CO2, water) excreted via lungs and kidneys. Magnesium and other electrolytes are removed via peritoneal dialysis; net elimination varies with dialysis prescription.
Peritoneal dialysis fluid components: dextrose is metabolized to CO2 and water; lactate is converted to bicarbonate in liver; electrolytes are variably reabsorbed. ~70% of administered dextrose is absorbed; elimination primarily via metabolic pathways.
Dextrose: negligible binding. Magnesium: ~30% bound to albumin; Low Magnesium formulation minimizes magnesium load.
Dextrose: negligible; lactate: <10% bound to albumin.
Dextrose: Vd ~0.2-0.3 L/kg (total body water). Magnesium: Vd ~0.5-0.7 L/kg. Clinical meaning: Distributes into extracellular fluid; low Vd reflects limited tissue distribution.
Dextrose: Vd ~0.25 L/kg (total body water); lactate: Vd ~0.5 L/kg.
Intraperitoneal: dextrose absorption is 60-80% over a dwell; systemically bioavailable as absorbed glucose. Not applicable for IV or other routes.
Not applicable: intraperitoneal administration bypasses gastrointestinal absorption; dextrose absorption ~70-80% of administered dose over dwell time.
No dose adjustment for renal impairment; drug is administered intraperitoneally for peritoneal dialysis. Monitor serum electrolytes and ultrafiltration.
Dosing is titrated based on residual renal function and peritoneal dialysis adequacy. For patients with GFR <10 mL/min, standard regimen is used. Adjust exchange volume and number to achieve weekly Kt/V ≥1.7.
No specific adjustment; caution in hepatic impairment due to risk of lactate metabolism impairment with dextrose. Monitor serum lactate and electrolytes.
No specific Child-Pugh based dose adjustments; monitor for glucose intolerance and fluid overload. In severe hepatic impairment, consider reduced dextrose concentration to avoid hyperglycemia.
Weight-based: 30-40 mL/kg per exchange, 4-5 exchanges daily. Adjust dextrose concentration based on ultrafiltration target. Low magnesium product used if hypermagnesemia risk.
Initial exchange volume: 10-20 mL/kg per exchange, up to 1100 mL/m² body surface area per exchange. Number of exchanges: 4-5 per day. Titrate based on ultrafiltration and metabolic control.
No specific dose adjustment; monitor fluid status, electrolytes, and ultrafiltration volume closely due to increased risk of volume overload and electrolyte disturbances.
Start with lower exchange volumes (1.5-2 liters) and monitor for fluid overload and electrolyte imbalances. Adjust dextrose concentration to minimize hyperglycemia. Use same exchange frequency as adults.
None
None
["Not for intravenous use","Risk of peritonitis","Electrolyte imbalance (hypokalemia, hypomagnesemia, hypocalcemia)","Fluid overload or dehydration","Hyperglycemia, especially in diabetic patients","Abdominal wall hernias","Ileus or mechanical obstruction","Encapsulating peritoneal sclerosis (rare)"]
Peritonitis risk; monitor for hyperglycemia, volume overload, hypokalemia, hypomagnesemia, and acidosis; strict aseptic technique; not for IV use; monitor serum electrolytes and glucose.
["Pre-existing severe hypokalemia","Hypercalcemia","Severe hyperglycemia uncorrected","Significant abdominal adhesions or fibrosis","Pre-existing peritoneal diaphragmatic defects","History of severe pancreatitis or diverticulitis","Inability to perform dialysis exchanges safely"]
Pre-existing severe lactic acidosis, hypersensitivity to any component, documented inability to perform peritoneal dialysis, recent abdominal surgery with prosthetic material, severe abdominal wall infection or burn, pregnancy (relative).
Data Pending Review
Data Pending Review
No direct food interactions with the solution itself, but dietary management is critical. Magnesium-restricted diet advised if serum magnesium is elevated; avoid high-magnesium foods like nuts, seeds, legumes, whole grains, chocolate, bananas, and dark leafy greens. Dextrose content may affect glycemic control; diabetic patients should monitor carbohydrate intake and adjust insulin as needed. Potassium and phosphorus restrictions may also apply based on individual lab values.
No direct dietary interactions with the dialysis solution itself. However, patients on peritoneal dialysis should follow a renal diet: limit sodium, potassium, phosphorus, and fluid intake as advised. Avoid high-phosphorus foods (dairy, nuts, colas) and high-potassium foods (bananas, oranges, potatoes). Use salt substitutes only if recommended, as they may contain potassium. Maintain adequate protein intake unless restricted. Consult a renal dietitian for individualized meal planning.
Delflex with Dextrose 4.25% Low Magnesium is a peritoneal dialysis solution. There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies have not been conducted with this solution. In general, peritoneal dialysis may cause electrolyte disturbances and fluid shifts that could affect fetal well-being. Hyperglycemia from dextrose absorption may pose risks during organogenesis (first trimester) and later trimesters. Use only if clearly needed and monitor maternal glucose and electrolytes closely.
Peritoneal dialysis solutions are generally considered low risk due to minimal systemic absorption. No specific teratogenic effects reported; however, electrolyte imbalances or metabolic disturbances from improper use could theoretically affect fetal development. Use only if clearly indicated.
It is not known whether Delflex components are excreted in human milk. Dextrose is a normal constituent of milk. Calcium, magnesium, and sodium are present in milk and the additional amounts from dialysis are likely negligible. However, due to potential for systemic absorption of dextrose and electrolyte shifts, caution is advised. No M/P ratio is available.
No data on excretion into breast milk. Clinically insignificant systemic absorption suggests minimal risk to nursing infant. Caution with additives (e.g., dextrose, electrolytes). M/P ratio not available.
Dosing of peritoneal dialysis solution (volume, dwell time, number of exchanges) should be individualized based on maternal renal function, electrolyte status, and glycemic control. Pregnancy may require increased dialysis dose due to increased metabolic demands and volume of distribution. Monitor blood glucose closely as dextrose absorption can cause hyperglycemia; insulin adjustment may be necessary. No specific dose adjustment of the solution is defined; clinical judgment and frequent monitoring are required.
No standard dose adjustments required due to minimal systemic absorption. However, increased maternal plasma volume and altered electrolyte needs may necessitate adjustment of dialysis prescription (e.g., dextrose concentration, volume) to avoid hypoglycemia, hyperglycemia, or electrolyte disturbances. Individualize based on maternal and fetal status.
Category C
Category C
DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM is a peritoneal dialysis solution indicated for patients with end-stage renal disease (ESRD) to remove waste products and excess fluid via the peritoneal membrane. The low magnesium formulation (0.5 mEq/L) is specifically designed for patients at risk of hypermagnesemia, such as those with impaired renal function or on magnesium-containing medications. Monitor serum magnesium levels regularly; hypomagnesemia is also possible if dietary intake is insufficient. The 4.25% dextrose concentration provides the highest ultrafiltration capacity among standard solutions, making it suitable for fluid overload states. Use with caution in patients with severe hyperglycemia or glucose intolerance, as the dextrose load may elevate blood glucose. Ensure sterile technique during bag exchange to prevent peritonitis.
DELFLEX-LM W/ DEXTROSE 2.5% is a peritoneal dialysis solution with low magnesium (0.5 mEq/L) and low calcium (2.5 mEq/L), suitable for patients with hypercalcemia or to reduce calcium load. Monitor serum electrolytes, especially potassium and magnesium, during therapy. Do not use if solution is discolored or contains particulate matter. Warm solution to body temperature before use to reduce discomfort. Use aseptic technique to prevent peritonitis. Verify correct dextrose concentration to avoid unintended hyperglycemia.
Wash hands thoroughly before handling the dialysis bag or catheter site.Inspect the solution bag for cloudiness, discoloration, or leaks; do not use if present.Use only as directed by your healthcare provider about the number and duration of exchanges.Report any signs of infection such as redness, swelling, or drainage at the catheter site, or abdominal pain, fever, or nausea.Monitor your blood glucose levels if you have diabetes, as the dextrose in the solution may raise blood sugar.Follow a kidney-friendly diet as recommended, which may include limiting certain foods high in magnesium (e.g., nuts, seeds, leafy greens) if your magnesium levels are high.Do not reuse the dialysis bag or tubing; dispose as instructed.Keep a log of your daily weight and report any rapid weight gain or persistent edema.Avoid vigorous exercise that could dislodge the catheter.Seek immediate medical attention if you experience shortness of breath, chest pain, or severe abdominal pain.
Inspect the bag for any leaks or cloudy solution before use; do not use if damaged or discolored.Warm the solution to body temperature (approximately 37°C) by placing the bag in a warm water bath—do not microwave.Wash hands thoroughly and use sterile technique when connecting and disconnecting the dialysis lines.Report any signs of infection such as fever, abdominal pain, or cloudy drainage fluid immediately.Monitor blood glucose regularly as the dextrose in the solution can raise blood sugar.Adhere to the prescribed dialysis schedule and do not skip or extend exchanges without medical advice.